RESUMO
BACKGROUND AND OBJECTIVE: Histone Deacetylases (HDACs) are important therapeutic targets for many types of human cancers. A derivative of valproic acid, N-(2-hydroxyphenyl)-2-propylpentanamide (HOAAVPA), has antiproliferative properties on some cancer cell lines and inhibits the HDAC1 isoform. MATERIALS AND METHODS: In this work, HO-AAVPA was tested as an antiproliferative agent in U87-MG (human glioblastoma) and U-2 OS cells (human osteosarcoma), which are types of cancer that are difficult to treat, and its antiangiogenic properties were explored. RESULTS: HO-AAVPA had antiproliferative effects at 48h with an IC50=0.655mM in U87-MG cells and an IC50=0.453mM in U-2 OS cells. Additionally, in the colony formation assay, HO-AAVPA decreased the number of colonies by approximately 99% in both cell lines and induced apoptosis by 31.3% in the U-2 OS cell line and by 78.2% in the U87-MG cell line. Additionally, HO-AAVPA reduced the number of vessels in Chorioallantoic Membranes (CAMs) by approximately 67.74% and IL-6 levels in both cell lines suggesting that the biochemical mechanism on cancer cell of HO-AAVPA is different compared to VPA. CONCLUSION: HO-AAVPA has antiproliferative effects on glioblastoma and osteosarcoma and antiangiogenic properties.
Assuntos
Inibidores da Angiogênese/farmacologia , Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Neovascularização Patológica/tratamento farmacológico , Amidas/antagonistas & inibidores , Inibidores da Angiogênese/síntese química , Inibidores da Angiogênese/química , Antineoplásicos/síntese química , Antineoplásicos/química , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Estrutura Molecular , Neovascularização Patológica/induzido quimicamente , Neovascularização Patológica/patologia , Pentanos/antagonistas & inibidores , Relação Estrutura-Atividade , Células Tumorais CultivadasRESUMO
Therapeutic strategies for the treatment of any severe disease are based on the discovery and validation of druggable targets. The human genome encodes only 600-1500 targets for small-molecule drugs, but posttranslational modifications lead to a considerably larger druggable proteome. The spontaneous conversion of asparagine (Asn) residues to aspartic acid or isoaspartic acid is a frequent modification in proteins as part of the process called deamidation. Triosephosphate isomerase (TIM) is a glycolytic enzyme whose deamidation has been thoroughly studied, but the prospects of exploiting this phenomenon for drug design remain poorly understood. The purpose of this study is to demonstrate the properties of deamidated human TIM (HsTIM) as a selective molecular target. Using in silico prediction, in vitro analyses, and a bacterial model lacking the tim gene, this study analyzed the structural and functional differences between deamidated and nondeamidated HsTIM, which account for the efficacy of this protein as a druggable target. The highly increased permeability and loss of noncovalent interactions of deamidated TIM were found to play a central role in the process of selective enzyme inactivation and methylglyoxal production. This study elucidates the properties of deamidated HsTIM regarding its selective inhibition by thiol-reactive drugs and how these drugs can contribute to the development of cell-specific therapeutic strategies for a variety of diseases, such as COVID-19 and cancer.
Assuntos
Infecções por Coronavirus/tratamento farmacológico , Inibidores Enzimáticos/farmacologia , Neoplasias/tratamento farmacológico , Pneumonia Viral/tratamento farmacológico , Bibliotecas de Moléculas Pequenas/farmacologia , Triose-Fosfato Isomerase/antagonistas & inibidores , Amidas/antagonistas & inibidores , Amidas/metabolismo , COVID-19 , Cristalografia por Raios X , Inibidores Enzimáticos/química , Humanos , Modelos Moleculares , Mutação , Pandemias , Proteoma/antagonistas & inibidores , Proteoma/genética , Proteoma/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/isolamento & purificação , Proteínas Recombinantes/metabolismo , Bibliotecas de Moléculas Pequenas/química , Triose-Fosfato Isomerase/química , Triose-Fosfato Isomerase/metabolismoRESUMO
Epithelial folding transforms simple sheets of cells into complex three-dimensional tissues and organs during animal development. Epithelial folding has mainly been attributed to mechanical forces generated by an apically localized actomyosin network, however, contributions of forces generated at basal and lateral cell surfaces remain largely unknown. Here we show that a local decrease of basal tension and an increased lateral tension, but not apical constriction, drive the formation of two neighboring folds in developing Drosophila wing imaginal discs. Spatially defined reduction of extracellular matrix density results in local decrease of basal tension in the first fold; fluctuations in F-actin lead to increased lateral tension in the second fold. Simulations using a 3D vertex model show that the two distinct mechanisms can drive epithelial folding. Our combination of lateral and basal tension measurements with a mechanical tissue model reveals how simple modulations of surface and edge tension drive complex three-dimensional morphological changes.
Assuntos
Drosophila/crescimento & desenvolvimento , Células Epiteliais/citologia , Epitélio/anatomia & histologia , Epitélio/embriologia , Morfogênese , Estresse Mecânico , Actinas/metabolismo , Actomiosina , Amidas/antagonistas & inibidores , Animais , Fenômenos Biomecânicos , Padronização Corporal/genética , Divisão Celular , Proliferação de Células , Forma Celular , Tamanho Celular , Drosophila/anatomia & histologia , Drosophila/embriologia , Drosophila/genética , Proteínas de Drosophila/genética , Proteínas de Drosophila/metabolismo , Células Epiteliais/efeitos dos fármacos , Epitélio/efeitos dos fármacos , Matriz Extracelular , Discos Imaginais/crescimento & desenvolvimento , Larva/citologia , Larva/metabolismo , Terapia a Laser , Modelos Anatômicos , Modelos Biológicos , Piridinas/antagonistas & inibidoresRESUMO
HIV-1 entry into host cells starts with interactions between the viral envelope glycoprotein (Env) and cellular CD4 receptors and coreceptors. Previous work has suggested that efficient HIV entry also depends on intracellular signaling, but this remains controversial. Here we report that formation of the pre-fusion Env-CD4-coreceptor complexes triggers non-apoptotic cell surface exposure of the membrane lipid phosphatidylserine (PS). HIV-1-induced PS redistribution depends on Ca2+ signaling triggered by Env-coreceptor interactions and involves the lipid scramblase TMEM16F. Externalized PS strongly promotes Env-mediated membrane fusion and HIV-1 infection. Blocking externalized PS or suppressing TMEM16F inhibited Env-mediated fusion. Exogenously added PS promoted fusion, with fusion dependence on PS being especially strong for cells with low surface density of coreceptors. These findings suggest that cell-surface PS acts as an important cofactor that promotes the fusogenic restructuring of pre-fusion complexes and likely focuses the infection on cells conducive to PS signaling.
Assuntos
Infecções por HIV/virologia , HIV-1/fisiologia , HIV-1/patogenicidade , Fusão de Membrana/fisiologia , Fosfatidilserinas/metabolismo , Ativação Viral/fisiologia , Internalização do Vírus , Amidas/antagonistas & inibidores , Anoctaminas/metabolismo , Anticorpos Monoclonais , Benzilaminas , Antígenos CD4/metabolismo , Cálcio/metabolismo , Linhagem Celular , Membrana Celular/metabolismo , Ciclamos , Células HEK293 , Células HeLa , Compostos Heterocíclicos/antagonistas & inibidores , Interações Hospedeiro-Patógeno/fisiologia , Humanos , Proteínas de Transferência de Fosfolipídeos/metabolismo , Compostos de Amônio Quaternário/antagonistas & inibidores , Receptores CCR5/efeitos dos fármacos , Receptores CCR5/imunologia , Receptores CXCR4/efeitos dos fármacos , Transdução de Sinais , Proteínas do Envelope Viral/metabolismo , Ligação Viral , Replicação Viral/fisiologiaRESUMO
To elucidate the role of Na(+)/Ca(2+) exchanger (NCX) in neurite outgrowth, we investigated the effects of NCX inhibitors on neurite outgrowth in PC12 cells. KB-R7943 and 3',4'-dichlorobenzamil, NCX inhibitors, inhibited the neurite outgrowth caused by nerve growth factor (NGF). NCX inhibitors inhibited the neurite outgrowth caused by dibutylyl cAMP, which rapidly reorganizes the cytoskeleton. KB-R7943 inhibited the neurite outgrowth caused by Y-27632, an inhibitor of Rho kinase (ROCK) that regulates actin. However, NCX inhibitors did not inhibit NGF-induced phosphorylation of extracellular signal-regulated kinase. These results suggest that NCX inhibitor affects downstream of the Rho-ROCK signal transduction pathways in neurite outgrowth.
Assuntos
Proteínas do Tecido Nervoso/antagonistas & inibidores , Neuritos/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Trocador de Sódio e Cálcio/antagonistas & inibidores , Amidas/antagonistas & inibidores , Amidas/farmacologia , Amilorida/análogos & derivados , Amilorida/farmacologia , Animais , Bucladesina/antagonistas & inibidores , Bucladesina/farmacologia , Citoesqueleto/efeitos dos fármacos , Microscopia de Contraste de Fase , Fator de Crescimento Neural/antagonistas & inibidores , Fator de Crescimento Neural/metabolismo , Neuritos/metabolismo , Neuritos/ultraestrutura , Neurônios/metabolismo , Neurônios/ultraestrutura , Concentração Osmolar , Células PC12 , Inibidores de Proteínas Quinases/antagonistas & inibidores , Inibidores de Proteínas Quinases/farmacologia , Piridinas/antagonistas & inibidores , Piridinas/farmacologia , Ratos , Tioureia/análogos & derivados , Tioureia/farmacologia , Quinases Associadas a rho/antagonistas & inibidoresRESUMO
PURPOSE: Bimatoprost is a widely used ocular hypotensive agent to treat glaucoma. It lowers intraocular pressure in humans by increasing both pressure-independent (uveoscleral) and pressure-dependent (conventional) aqueous humor outflow. The present study specifically examines bimatoprost effects on the cells that populate human outflow tissues. METHODS: The authors tested for prostamide receptor activation in primary cultures of human trabecular meshwork (TM), Schlemm's canal (SC), and ciliary smooth muscle (CSM) cells using cellular dielectric spectroscopy (CDS). RESULTS: The authors observed that bimatoprost produced an immediate and concentration-dependent increase in cell monolayer impedance for TM, SC, and CSM cells with EC(50) values of 4.3, 1.2, and 1.7 nM, respectively; corresponding to decreased cell contractility. Notably, in TM, SC, and CSM cells, bimatoprost was approximately equipotent to the selective FP receptor agonists fluprostenol and 17-phenyl PGF(2α). Bimatoprost effects were insensitive to cholera toxin and pertussis toxin but were abolished by phorbol 12-myristate 13-acetate pretreatment, suggesting Gq-involvement in cell signaling. The effects of bimatoprost on TM and SC cells were inhibited by the prostamide receptor antagonist AGN211334, with IC(50) values of 1.2 and 3.3 µM, respectively. Interestingly, AGN211334 behaved as an apparent inverse agonist in CDS assays involving TM cells but as a neutral prostamide antagonist with SC cells. CONCLUSIONS: Taken together, results suggest that bimatoprost specifically activates receptors in both cell types of the human conventional outflow pathway to modify intraocular pressure. However, only TM cell monolayers appear to have autocrine, or agonist-independent, receptor signaling that is sensitive to a prostamide receptor antagonist.
Assuntos
Amidas/farmacologia , Anti-Hipertensivos/farmacologia , Humor Aquoso/metabolismo , Corpo Ciliar/efeitos dos fármacos , Cloprostenol/análogos & derivados , Córnea/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Malha Trabecular/efeitos dos fármacos , Actinas/metabolismo , Adulto , Idoso , Amidas/antagonistas & inibidores , Anti-Hipertensivos/antagonistas & inibidores , Bimatoprost , Células Cultivadas , Corpo Ciliar/metabolismo , Cloprostenol/antagonistas & inibidores , Cloprostenol/farmacologia , Córnea/metabolismo , Relação Dose-Resposta a Droga , Impedância Elétrica , Humanos , Lactente , Pressão Intraocular/efeitos dos fármacos , Pessoa de Meia-Idade , Músculo Liso/metabolismo , Receptores de Prostaglandina/metabolismo , Doadores de Tecidos , Malha Trabecular/metabolismoRESUMO
RATIONALE: It has been proposed that cannabinoid-1 receptor inverse agonists might be effective for smoking cessation. We evaluated this hypothesis with the cannabinoid-1 receptor inverse agonist taranabant. METHODS: Adults who smoked > or =10 cigarettes a day for >1 year and had an expired CO level of > or =10 ppm participated in a randomized, double-blind, 8-week, study of taranabant (N = 159) or placebo (N = 158). Taranabant was titrated from 2 mg once daily to 8 mg once daily. Patients received smoking cessation counseling. The primary efficacy endpoint was continuous abstinence, defined as no cigarettes assessed by daily patient self-report and verified by breath CO level (<10 ppm) and plasma cotinine test (<10 ng/ml), during the last 4 weeks of the 8-week treatment period. RESULTS: The percentage of patients achieving continuous abstinence was 7.5% for taranabant 2-8 mg and 6.3% for placebo (odds ratio = 1.2 [90% confidence interval (CI), 0.6, 2.5], P = 0.678). Change from baseline in body weight in the taranabant 2-8-mg group was -1.5 (90% CI, -1.8, -1.3) versus 0.6 kg (90% CI, 0.4, 0.9) in the placebo group. Compared to placebo, taranabant 2-8 mg was associated with an increased incidence of psychiatric-related adverse events (e.g., depression, 8.2% versus 2.5%, P = 0.048), gastrointestinal-related adverse events (e.g., nausea, 49.7% versus 19.0%, P < 0.001), and flushing/hot flash adverse events (10.7% versus 1.9%, P = 0.002). CONCLUSIONS: Taranabant 2-8 mg did not improve smoking cessation and was associated with increased incidences of psychiatric-related, gastrointestinal-related, and flushing adverse events (ClinicalTrials.gov NCT00109135).
Assuntos
Amidas/uso terapêutico , Comportamento Aditivo/tratamento farmacológico , Piridinas/uso terapêutico , Abandono do Hábito de Fumar/métodos , Tabagismo/tratamento farmacológico , Adolescente , Adulto , Idoso , Amidas/efeitos adversos , Amidas/antagonistas & inibidores , Peso Corporal/efeitos dos fármacos , Relação Dose-Resposta a Droga , Método Duplo-Cego , Agonismo Inverso de Drogas , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Piridinas/efeitos adversos , Piridinas/antagonistas & inibidores , Receptor CB1 de Canabinoide/antagonistas & inibidoresRESUMO
For a series of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV ADME properties were improved by the incorporation of amide replacements. These efforts led to a novel series of potent and selective inhibitors of DPP-4 that exhibit an attractive pharmacokinetic profile and show excellent efficacy in an animal model of diabetes.
Assuntos
Amidas/química , Aminobutiratos/química , Inibidores da Dipeptidil Peptidase IV , Relação Estrutura-Atividade , Amidas/antagonistas & inibidores , Células CACO-2 , Linhagem Celular Tumoral , Química Farmacêutica , Diabetes Mellitus Tipo 2/tratamento farmacológico , Inibidores da Dipeptidil Peptidase IV/uso terapêutico , Desenho de Fármacos , Humanos , Hipoglicemiantes/antagonistas & inibidores , Hipoglicemiantes/uso terapêutico , Inibidores de Proteases/farmacocinética , Inibidores de Proteases/farmacologia , Canais de Sódio/metabolismoRESUMO
The overall purpose of hypertension treatment is 2-fold. First, patients often have symptoms that are related to their high blood pressure and although subtle in many instances may be improved dramatically by blood pressure control. The main reason for blood pressure treatment, however, is to reduce the burden of cardiovascular complications and end organ damage related to the condition. This may be considered the ultimate goal of blood pressure treatment. In this respect, actual blood pressure measurements may be seen as surrogate end points as the organ protective effects of two antihypertensive agents may differ significantly even though their blood pressure lowering effects are similar. Thus beta-blockers, once seen as first-line treatment of hypertension for most patients, now are considered as third- or fourthline agents according to the latest NICE guidelines (National Institute for Health and Clinical Excellence, www.nice.org.uk/CG034). On the other hand, agents that inhibit the activity of the renin-angiotensin-aldosterone system (RAAS) system are being established as safe, effective and end organ protective in numerous clinical trials, resulting in their general acceptance as first-line treatment in most patients with stage 2 hypertension. This shift in emphasis from beta-blockers and thiazide diuretics is supported by numerous clinical trials and has proven safe and well tolerated by patients. The impact of this paradigm shift will have to be established in future long-term randomized clinical trials. The optimal combination treatment with respect to end organ protection has yet to be determined. Most combinations will include either a RAAS active agent and calcium channel blocker or two separate RAAS active agents working at different levels of the cascade. In this respect direct renin inhibitors and angiotensin receptor blockers seem particularly promising but the concept awaits evaluation in upcoming randomized clinical trials. Although safety data from the randomized clinical trials to date have been promising, we still lack data on the long-term effect of aliskiren on mortality and there still are patient groups where the safety of aliskiren is unexplored.
Assuntos
Amidas/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Fumaratos/uso terapêutico , Hipertensão/tratamento farmacológico , Sistema Renina-Angiotensina/efeitos dos fármacos , Idoso , Idoso de 80 Anos ou mais , Amidas/administração & dosagem , Amidas/antagonistas & inibidores , Amidas/farmacologia , Anti-Hipertensivos/administração & dosagem , Anti-Hipertensivos/antagonistas & inibidores , Anti-Hipertensivos/farmacologia , Fumaratos/administração & dosagem , Fumaratos/antagonistas & inibidores , Fumaratos/farmacologia , Humanos , Estados UnidosRESUMO
Selective androgen receptor modulators (SARMs) are essentially prostate sparing androgens, which provide therapeutic potential in osteoporosis, male hormone replacement, and muscle wasting. Herein we report crystal structures of the androgen receptor (AR) ligand-binding domain (LBD) complexed to a series of potent synthetic nonsteroidal SARMs with a substituted pendant arene referred to as the B-ring. We found that hydrophilic B-ring para-substituted analogs exhibit an additional region of hydrogen bonding not seen with steroidal compounds and that multiple halogen substitutions affect the B-ring conformation and aromatic interactions with Trp741. This information elucidates interactions important for high AR binding affinity and provides new insight for structure-based drug design.
Assuntos
Amidas/química , Química Farmacêutica/métodos , Receptores Androgênicos/metabolismo , Amidas/antagonistas & inibidores , Caquexia/tratamento farmacológico , Cristalografia por Raios X/métodos , Desenho de Fármacos , Humanos , Ligantes , Masculino , Modelos Químicos , Conformação Molecular , Músculos/patologia , Osteoporose/tratamento farmacológico , Estrutura Terciária de Proteína , Receptores Androgênicos/químicaRESUMO
PURPOSE: Despite structural similarity with prostaglandin F(2 alpha), the ocular hypotensive agent bimatoprost (Lumigan; Allergan, Inc., Irvine, CA) shows unique pharmacology in vitro and functional activity in vivo. Unfortunately, the precise mechanisms that underlie bimatoprost's distinctive impact on aqueous humor dynamics are unclear. The purpose of the present study was to investigate the effects of bimatoprost and a novel prostamide-selective antagonist AGN 211334 on human conventional drainage. METHODS: Two model systems were used to test the consequences of bimatoprost and/or AGN 211334 treatment on conventional drainage. Human anterior segments in organ culture were perfused at a constant flow rate of 2.5 microL/min while pressure was recorded continuously. After stable baseline facilities were established, segments were treated with drug(s), and pressure was monitored for an additional 3 days. In parallel, the drugs' effects on hydraulic conductivity of human trabecular meshwork (TM) cell monolayers were evaluated. Pharmacological properties of AGN 211334 were characterized in isolated feline iris preparations in organ culture and heterologously expressed G-protein-coupled receptors were examined in vitro. RESULTS: Bimatoprost increased outflow facility by an average of 40% +/- 10% within 48 hours of treatment (n = 10, P < 0.001). Preincubation or coincubation with AGN 211334 significantly blunted bimatoprost's effects by 95% or 43%, respectively. Similar results were obtained in cell culture experiments in which bimatoprost increased hydraulic conductivity of TM cell monolayers by 78% +/- 25%. Pretreatment with AGN 211334 completely blocked bimatoprost's effects, while coincubation decreased its effects on average by 74%. In both models, AGN 211334 alone significantly decreased fluid flux across trabecular tissues and cells. CONCLUSIONS: The findings indicate that bimatoprost interacts with a prostamide receptor in the trabecular meshwork to increase outflow facility.
Assuntos
Amidas/farmacologia , Anti-Hipertensivos/farmacologia , Cloprostenol/análogos & derivados , Lipídeos/farmacologia , Malha Trabecular/efeitos dos fármacos , Idoso , Idoso de 80 Anos ou mais , Amidas/antagonistas & inibidores , Animais , Humor Aquoso/metabolismo , Bimatoprost , Cálcio/metabolismo , Sinalização do Cálcio/fisiologia , Gatos , Técnicas de Cultura de Células , Cloprostenol/antagonistas & inibidores , Cloprostenol/farmacologia , Dinoprosta/farmacologia , Dinoprostona/análogos & derivados , Dinoprostona/farmacologia , Feminino , Humanos , Pressão Intraocular/fisiologia , Iris/efeitos dos fármacos , Lipídeos/antagonistas & inibidores , Masculino , Pessoa de Meia-Idade , Contração Muscular/fisiologia , Músculo Liso/efeitos dos fármacos , Técnicas de Cultura de Órgãos , Oxazóis/farmacologia , Receptores de Tromboxanos/antagonistas & inibidores , Receptores de Tromboxanos/metabolismo , Proteínas Recombinantes , Malha Trabecular/metabolismoRESUMO
In the human coronary arteries, the intima begins to thicken from early adolescence and shows progressive thickening with age. We compared the response to vascular injury of the coronary and femoral arteries using a canine model. Both incorporation of 5-bromo-2'-deoxyuridine (BrdU) and neointimal formation after balloon injury were significantly greater in the coronary artery than in the femoral artery. Also, the proliferative and migratory activities of coronary smooth muscle cells (SMCs) were significantly greater than those of femoral SMCs in vitro. The level of phosphorylated myosin light chain (phospho-MLC) was higher in coronary SMCs than in femoral SMCs. Y-27632, a specific inhibitor of Rho-kinase, significantly inhibited the PDGF-induced migration of both coronary and femoral SMCs. In contrast, the migration of coronary SMCs, but not femoral SMCs, was inhibited by ML-9, a specific inhibitor of myosin light chain kinase (MLCK). These findings suggest that the contribution of Rho-kinase and MLCK differs between the different arteries. They also suggest that a neointima develops more easily in the coronary artery than in the femoral artery because of the greater proliferative and migratory activity of coronary SMCs. Differential activation of MLC might partly explain the increased proliferation and migration of coronary SMCs.
Assuntos
Vasos Coronários/citologia , Vasos Coronários/fisiopatologia , Artéria Femoral/citologia , Artéria Femoral/fisiopatologia , Miócitos de Músculo Liso/citologia , Amidas/antagonistas & inibidores , Amidas/farmacologia , Angioplastia Coronária com Balão/efeitos adversos , Animais , Anticoagulantes/farmacologia , Antimetabólitos/farmacologia , Becaplermina , Bromodesoxiuridina/farmacologia , Divisão Celular/fisiologia , Movimento Celular/fisiologia , Colesterol/administração & dosagem , Vasos Coronários/metabolismo , Modelos Animais de Doenças , Cães , Eletroforese em Gel de Poliacrilamida , Inibidores Enzimáticos/farmacologia , Feminino , Artéria Femoral/metabolismo , Imuno-Histoquímica , Peptídeos e Proteínas de Sinalização Intracelular , Modelos Cardiovasculares , Músculo Liso Vascular/citologia , Miócitos de Músculo Liso/metabolismo , Quinase de Cadeia Leve de Miosina/efeitos dos fármacos , Miosinas/efeitos dos fármacos , Fosforilação/efeitos dos fármacos , Fator de Crescimento Derivado de Plaquetas/farmacologia , Proteínas Serina-Treonina Quinases/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-sis , Piridinas/antagonistas & inibidores , Piridinas/farmacologia , Estatística como Assunto , Suínos , Fatores de Tempo , Túnica Íntima/citologia , Túnica Íntima/efeitos dos fármacos , Túnica Íntima/fisiopatologia , Quinases Associadas a rhoRESUMO
The absence of Gln-tRNA synthetase in certain bacteria necessitates an alternate pathway for the production of Gln-tRNA(Gln): misacylated Glu-tRNA(Gln) is transamidated by a Gln-dependent amidotransferase (Glu-AdT) via catalysis of Gln hydrolysis, ATP hydrolysis, activation of Glu-tRNA(Gln), and aminolysis of activated tRNA by Gln-derived NH(3). As observed for other Gln-coupled amidotransferases, substrate binding, Gln hydrolysis, and transamidation by Glu-AdT are tightly coordinated [Horiuchi, K. Y., Harpel, M. R., Shen, L., Luo, Y., Rogers, K. C., and Copeland, R. A. (2001) Biochemistry 40, 6450-6457]. However, Glu-AdT does not employ an active-site Cys nucleophile for Gln hydrolysis, as is common in all other glutaminases: some Glu-AdT lack Cys, but all contain a conserved Ser (Ser176 in the A subunit of Streptococcus pyogenes Glu-AdT) within a sequence signature motif of Ser-based amidases. Our current results with S. pyogenes Glu-AdT support this characterization of Glu-AdT as a Ser-based glutaminase. Slow-onset (approximately 50 M(-1) s(-1)), tight-binding (t(1/2) > 2.5 h for complex dissociation), Gln-competitive inhibition of the Glu-tRNA(Gln)/ATP-independent glutaminase activity of Glu-AdT by gamma-Glu boronic acid is consistent with engagement of a Ser nucleophile in the glutaminase active site. Conversion to rapidly reversible, yet still potent (K(i) = 73 nM) and Gln-competitive, inhibition under full transamidation conditions mirrors the coupling between Gln hydrolysis and aminolysis reactions during productive transamidation. Site-directed replacement of Ser176 by Ala abolishes glutaminase and Gln-dependent transamidase activities of Glu-AdT (>300-fold), but retains a wild-type level of NH(3)-dependent transamidation activity. These results demonstrate the essentiality of Ser176 for Gln hydrolysis, provide additional support for coordinated coupling of Gln hydrolysis and transamidase transition states during catalysis, and validate glutaminase-directed inhibition of Glu-AdT as a route for antimicrobial chemotherapy.
Assuntos
Glutaminase/química , Mutagênese Sítio-Dirigida , Transferases de Grupos Nitrogenados/antagonistas & inibidores , Transferases de Grupos Nitrogenados/genética , Serina/química , Streptococcus pyogenes/enzimologia , Streptococcus pyogenes/genética , Alanina/genética , Amidas/antagonistas & inibidores , Amidas/metabolismo , Sequência de Aminoácidos , Aminoaciltransferases/química , Sítios de Ligação/genética , Ligação Competitiva/genética , Ácidos Borônicos/antagonistas & inibidores , Ácidos Borônicos/química , Sequência Conservada , Glutamina/antagonistas & inibidores , Glutamina/metabolismo , Hidrólise/efeitos dos fármacos , Dados de Sequência Molecular , Transferases de Grupos Nitrogenados/metabolismo , Serina/genéticaRESUMO
BACKGROUND: Current studies provide evidence that a small G protein, RhoAp21, and its target protein, Rho-associated coiled-coil forming protein kinase (ROCK), regulate not only cell shape but also cell migration. However, contribution of Rho/ROCK signaling to graft rejection is unknown. The purpose of this study was to evaluate the inhibitory effect of Y-27632, a highly selective ROCK inhibitor, on rejection of heterotopic cardiac transplantation in mice. METHODS: BALB/c (H-2(d)) hearts were transplanted into C3H/He (H-2(k)) as allografts that were full histoincompatibility combinations. The recipients received several doses of Y-27632, commencing 1 day before cardiac transplantation until rejection. We used immunohistochemical study to detect the expression of myocardial intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), and we immunoenzymatically measured serum interleukin (IL)-6. Furthermore, we evaluated cardiac allograft vasculopathy treated with either FK506 or Y-27632 at Day 100. RESULTS: The Y-27632-treated (2 mg/kg/day) allografts prolonged the mean survival time (49.6 +/- 10.1 days, n = 12) as compared with the untreated allografts (8.1 +/- 0.4 days, n = 7, p < 0.001). Histologic examinations of the Y-27632-treated allografts at Day 7 showed greatly reduced leukocyte infiltration compared with the untreated allografts. The Y-27632-treated allografts revealed faint expression of myocardial ICAM-1 and VCAM-1 at Day 7. The serum IL-6 levels also decreased in the Y-27632-treated mice. In the long-surviving Y-27632-treated allografts at Day 100, we saw neither active rejection nor apparent thickening of vascular intima. CONCLUSION: Our results suggest that ROCK plays a major role in cardiac rejection in the BALB/c-to-C3H/He mouse model. Inhibition of this Rho/ROCK signaling may be an alternative therapeutic option for managing acute and chronic rejection.
Assuntos
Amidas/antagonistas & inibidores , Inibidores Enzimáticos/uso terapêutico , Transplante de Coração/mortalidade , Piridinas/antagonistas & inibidores , Transplante Heterotópico/mortalidade , Animais , Anticorpos/efeitos dos fármacos , Anticorpos/imunologia , Modelos Animais de Doenças , Rejeição de Enxerto/tratamento farmacológico , Rejeição de Enxerto/mortalidade , Sobrevivência de Enxerto/efeitos dos fármacos , Transplante de Coração/imunologia , Transplante de Coração/patologia , Imuno-Histoquímica , Molécula 1 de Adesão Intercelular/efeitos dos fármacos , Molécula 1 de Adesão Intercelular/imunologia , Interleucina-6/sangue , Leucócitos/efeitos dos fármacos , Leucócitos/imunologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C3H , Modelos Cardiovasculares , Transplante Heterotópico/patologia , Transplante Homólogo , Molécula 1 de Adesão de Célula Vascular/efeitos dos fármacos , Molécula 1 de Adesão de Célula Vascular/imunologiaAssuntos
Fármacos Anti-HIV/farmacologia , HIV-1/fisiologia , Fusão de Membrana/efeitos dos fármacos , Receptores de HIV/efeitos dos fármacos , Amidas/antagonistas & inibidores , HIV-1/efeitos dos fármacos , Humanos , Compostos de Amônio Quaternário/antagonistas & inibidores , Receptores de HIV/metabolismo , Proteínas do Envelope Viral/metabolismoRESUMO
Oligonucleotide N3'->P5' Phosphoramidates (PN) may confer advantages over unmodified phosphodiester compounds for therapeutic applications (1). Previous in vitro data demonstrated that PN Oligodeoxynucleotides (ODNs) possess several advantageous features, including RNase H-independence, an improved resistance to nuclease degradation, decreased protein binding, and high affinity sequence-specific binding to complementary RNAs (1, 2). Consequently, we undertook a study to investigate the effects of PN antisense (AS) oligos targeted against the p65 subunit of the Nuclear Factor Kappa beta (NF-kappaB) transcription factor in vivo, in mice. The ability of the antisense molecules to inhibit IL-6 elevation induced by lipopolysaccharide (LPS) in mice, was studied. A 16 mer uniformly modified PN and a chimeric phosphoramidate-phosphodiester oligodeoxynucleotide complementary to the region surrounding the starting codon, (PN-PO-PN) of the NK-kappaB p65 subunit mRNA, both caused a sequence specific reduction of the serum IL-6 level in mice. A scrambled oligodeoxynucleotide showed much lower IL-6 inhibition in mice. These results show that the p65 PN-AS can modulate expression of IL-6 in mice without uptake enhancers and therefore may be a useful prototype for RNAse-H independent therapeutic agents.
Assuntos
Amidas/antagonistas & inibidores , Regulação da Expressão Gênica , Interleucina-6/biossíntese , NF-kappa B/genética , Oligonucleotídeos Antissenso/genética , Oligonucleotídeos Antissenso/farmacologia , Ácidos Fosfóricos/antagonistas & inibidores , Animais , Regulação da Expressão Gênica/efeitos dos fármacos , Interleucina-6/antagonistas & inibidores , Interleucina-6/genética , Camundongos , NF-kappa B/antagonistas & inibidoresRESUMO
N-Arachidonoylethanolamine (anandamide; AEA) and 2-arachidonoylglycerol (2-AG), the two proposed endogenous agonists of cannabinoid receptors, and the putative AEA biosynthetic precursor, N-arachidonoylphosphatidylethanolamine (NArPE), were identified in bovine retina by means of gas chromatography-electron impact mass spectrometry (GC-EIMS). This technique also allowed us to identify N-docosahexanoylethanolamine (DHEA) and 2-docosahexanoylglycerol (2-DHG), two derivatives of docosahexaenoic acid (DHA), one of the most abundant fatty acids esterified in retina phospholipids and necessary for optimal retinal function. N-Docosahexaenoylphosphatidylethanolamine (NDHPE), the potential biosynthetic precursor for DHEA, was also found. The fatty acid composition of the sn-1 and sn-2 positions of bovine retina's most abundant phospholipid classes, also determined here, were in agreement with a phospholipid-dependent mechanism for 2-AG, 2-DHG, AEA, and DHEA biosynthesis, as very high levels of polyunsaturated fatty acids, including DHA, were found on the sn-2 position of phosphatidylcholine (PC) and -ethanolamine (PE), and measurable amounts of di-docosahexanoyl-PC and -PE, two potential biosynthetic precursors of NDHPE, were detected. Accordingly, we found that isolated particulate fractions from bovine retina could release AEA and DHEA in a time-dependent fashion. Finally, a fatty acid amide hydrolase (FAAH)-like activity with subcellular distribution and pH dependency similar to those reported for the brain enzyme was also detected in bovine retina. This activity was inhibited by FAAH inhibitors, phenylmethylsulfonyl fluoride and arachidonoyltrifluoromethylketone, and appeared to recognize DHEA with a lower efficiency than AEA. These data indicate that AEA and its congeners may play a physiological role in the mammalian eye.
Assuntos
Amidas/antagonistas & inibidores , Amidas/metabolismo , Ácidos Araquidônicos/antagonistas & inibidores , Ácidos Araquidônicos/biossíntese , Etanolaminas/antagonistas & inibidores , Etanolaminas/metabolismo , Retina/metabolismo , Amidoidrolases/metabolismo , Animais , Canabinoides/metabolismo , Bovinos , Ácidos Docosa-Hexaenoicos/metabolismo , Endocanabinoides , Ácidos Graxos/análise , Cromatografia Gasosa-Espectrometria de Massas , Glicerídeos/metabolismo , Técnicas In Vitro , Cinética , Fosfatidilcolinas/química , Fosfatidilcolinas/metabolismo , Fosfatidiletanolaminas/química , Fosfatidiletanolaminas/metabolismo , Alcamidas Poli-Insaturadas , Receptores de Canabinoides , Receptores de Droga/agonistasRESUMO
Immunoreactive glycine-extended CCK peptides are found in normal mouse cerebral cortex and are very abundant in some CCK expressing endocrine tumor cells in culture. The glycine-extended forms in mouse cortex and in cell lines mirror their respective amidated forms. Mouse cerebral cortex, mouse AtT20 and rat WE cells produce mainly CCK 8 amide and CCK 8 Gly. In contrast, mouse intestinal STC-1 cells produce CCK 22 and CCK 8 amide along with forms of CCK Gly which are slightly larger than their respective amidated forms. The CCK 8 Gly-like peptide from AtT20 cells, after desulfation, co-eluted on HPLC with unsulfated CCK 8 Gly. Addition of copper and ascorbate to culture medium of WE cells caused a small increase in secretion of amidated CCK, without changing cellular levels of this peptide. Treatment with the amidation inhibitor diethyldithiocarbamate greatly decreased cellular content and secretion of CCK amide while it increased cellular content and secretion of CCK Gly. These results provide further evidence that glycine-extended CCK peptides are the immediate precursors of amidated CCK peptides.
Assuntos
Amidas/antagonistas & inibidores , Amidas/metabolismo , Colecistocinina/metabolismo , Neoplasias das Glândulas Endócrinas/metabolismo , Glicina/metabolismo , Fragmentos de Peptídeos/isolamento & purificação , Animais , Carboxipeptidases/metabolismo , Células Cultivadas , Colecistocinina/química , Ditiocarb/farmacologia , Glândulas Endócrinas/citologia , Glândulas Endócrinas/metabolismo , Glicina/isolamento & purificação , Camundongos , Fragmentos de Peptídeos/metabolismo , Ratos , Células Tumorais CultivadasAssuntos
Prostaglandinas E/antagonistas & inibidores , Prostaglandinas F Sintéticas/farmacologia , Prostaglandinas F/antagonistas & inibidores , Amidas/antagonistas & inibidores , Amidas/síntese química , Amidas/farmacologia , Aminas/antagonistas & inibidores , Aminas/síntese química , Aminas/farmacologia , Animais , Colo/efeitos dos fármacos , Relação Dose-Resposta a Droga , Técnicas In Vitro , Contração Muscular/efeitos dos fármacos , Prostaglandinas F Sintéticas/síntese química , Relação Estrutura-AtividadeRESUMO
FMRFamide (phenylalanyl-methionyl-arginyl-phenylalanine amide) is a cardioexcitatory peptide recently isolated and identified in molluscan ganglia. Both FMRFamide and 5-hydroxytryptamine (5HT), the cardioexcitatory neurotransmitter in molluscs, were tested on the ventricle of the bivalve Mercenaria mercenaria. Both agents increased myocardial contractility, the intracellular cyclic AMP concentration of intact hearts and the adenylate cyclase activity of a myocardial membrane fraction. FMRFamide was 5--10 times more potent than 5HT. All of the effects of 5HT, and none of those of FMRFamide, were blocked by methysergide, a specific 5HT antagonist.